Quarterly report [Sections 13 or 15(d)]

NON CONTROLLING INTEREST (Tables)

NON CONTROLLING INTEREST (Tables)

6 Months Ended

Jun. 30, 2026

ROYALTY OBLIGATIONS NET

Schedule of net loss attributable to non-controlling interest

		BioCorRx Pharmaceuticals, Inc.				Joseph DeSanto MD
Net loss for the three months ended March 31, 2026		$	(269,652	)		$	-
Average Non-controlling interest percentage of profit/losses			24.2	%			35.0	%
Net loss attributable to the non-controlling interest			(65,256	)			-

Net loss for the three months ended June 30, 2026			(287,410	)			-
Average Non-controlling interest percentage of profit/losses			12.85	%			35.0	%
Net loss attributable to the non-controlling interest			(36,932	)			-

Total			(102,188	)			-

		BioCorRx Pharmaceuticals, Inc.				Joseph DeSanto MD
Net loss for the three months ended March 31, 2025		$	(42,784	)		$	(10	)
Average Non-controlling interest percentage of profit/losses			24.2	%			35.0	%
Net loss attributable to the non-controlling interest			(10,354	)			(3	)

Net loss for the three months ended June 30, 2025			(594,446	)			(5	)
Average Non-controlling interest percentage of profit/losses			24.2	%			35.0	%
Net loss attributable to the non-controlling interest			(143,856	)			(2	)

Total			(154,210	)			(5	)

Schedule of changes in non-controlling interest

Balance, December 31, 2025		$	(303,429	)
Net loss attributable to the non-controlling interest			(102,188	)
Acquisition of non-controlling interest by the Company			158,835
Balance, June 30, 2026			(246,782	)

Balance, December 31, 2024		$	(234,812	)
Net loss attributable to the non-controlling interest			(154,215	)
Balance, June 30, 2025			(389,027	)